Bone Health

Human studies link consumption of MK-7 found in MenaQ7® to improved bone health.


Reduction in bone health affects millions of people. Vitamin K2 plays a critical role in generating and maintaining healthy bone. MenaQ7® has been clinically demonstrated to contribute to building and replenishing bone in all stages of life.

Osteocalcin is a vitamin K-dependent protein that needs Vitamin K2 to function properly. Bone is a living tissue, and it is normal for bone throughout the entire skeleton to constantly be repaired and rebuilt (formation) as bone-breakdown (resorption) occurs. Osteocalcin binds calcium to the bone matrix and builds healthy bones.  Vitamin K-deficiency may lead to loss of calcium in the bone and reduced quality of bone, which leads to higher chances of fracture.

Populations that consume a significant amount of Vitamin K2 have stronger, healthier bones. However, the majority of people consuming typical Western diets – and even those who consume the healthiest diets – do not get sufficient Vitamin K2 from food and are therefore Vitamin K2 deficient. This deficiency manifests itself in higher rates of fractures and incidences of bone conditions, such as osteoporosis.

Bone-building combinations

Vitamins D and K2 work in in synergy to enable efficient use of Calcium for improved bone health.

Calcium is involved in many important biochemical processes in the body, including the maintenance of the skeleton. A steady supply of calcium is needed to keep up the constant repair and rebuilding of the skeleton, but calcium alone is insufficient for optimal bone health as shown in several studies measuring effect of calcium supplementation. The body optimizes the use of calcium with Vitamins D and K2. Vitamin D stimulates the synthesis of osteocalcin, whereas Vitamin K2 is needed for the activation of osteocalcin. Only Vitamin K2-activated osteocalcin will bind calcium optimally.

For more information on the link between MenaQ7® and bone health, visit

Contact Us

For further information regarding NattoPharma’s R&D activities, please contact:

William Sommer

VP, Global Development & Regulatory

NattoPharma contact information:
Main office: Lilleakerveien 2B, 0283 Oslo,Norway
North American Subsidary: 328 Amboy Ave.,Ste. D,Metuchen, NJ 08840
Tel: (+47) 40 00 90 08
Tel: (+1) 609-454-2992
Created by:
Nutricon logo.
Search term: